A Prospective, Single Centre, Observational, 12-months follow-up, clinical evaluation study to investigate the safety and performance of the M’Sure-S, Sirolimus Eluting Coronary Stent System in coronary artery lesion.

**Study Objectives-**1.      To prospectively analyse the safety profile of the M’SURE-S, Sirolimus Eluting Coronary Stent in patients who underwent percutaneous coronary intervention (PCI) for coronary artery lesions. To prospectively evaluate the performance of the M’SURE-S, Sirolimus Eluting Coronary Stent in terms of major adverse cardiovascular events (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), and clinical outcomes at 12-month follow-up.

Primary endpoint- Major Adverse Cardiac Events (MACE), defined as composite endpoint of cardiac death, Myocardial infarction (MI) and Target Lesion Revascularization (TLR) at 12 months.

Secondary endpoints- 1.      Clinical device and procedural success.

·         Device Success is defined as the achievement of a final residual in-stent diameter stenosis of < 30% (visual estimate).

·         Procedure success is defined as the achievement of a final in-stent diameter stenosis of < 30% (by visual estimate) without the occurrence of MACE during the hospital stay (up to 7 days if the subject still in the hospital).

2.      Telephonic follow up for all study patients at 12-months post-procedure.

3.      Composite rate of any death (cardiac death, vascular death, or non-cardiac death) at 12-months post-procedure.

4.      Composite rate of cardiac death, any target vessel MI (QMI or NQMI),

and TLR (PCI or CABG, CI vs. non-CI) at 12-months post-procedure.

5.      Device malfunctions at 12-months post-procedure.

6. Serious adverse events at 12-months post-procedure.